Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$39.80
0.020.05%
At close: -
$39.80
0.001200.00%
After Hours: 4:13 PM EDT
Comments
Loading...
Ionis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IONS | Benzinga
Ionis Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Ionis Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Guggenheim
Needham
Redburn Atlantic
1calculated from analyst ratings
Analyst Ratings for Ionis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor46% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2025 | Buy Now | — | JP Morgan | Jessica Fye67% | $45 → $48 | Maintains | Neutral | Get Alert |
| 05/20/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor46% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay55% | $65 → $64 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $50 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $55 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor46% | → $45 | Initiates | → Buy | Get Alert |
| 04/03/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay55% | — | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | — | Redburn Atlantic | Joshua Smith 69% | → $39 | Initiates | → Neutral | Get Alert |
| 03/24/2025 | Buy Now | — | JP Morgan | Jessica Fye67% | $47 → $45 | Maintains | Neutral | Get Alert |
| 03/11/2025 | Buy Now | — | JP Morgan | Jessica Fye67% | $51 → $47 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | — | Citigroup | David Lebowitz56% | $67 → $64 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | — | RBC Capital | Luca Issi45% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | — | BMO Capital | Kostas Biliouris34% | $60 → $45 | Maintains | Market Perform | Get Alert |
| 02/20/2025 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | — | RBC Capital | Luca Issi45% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | — | Piper Sandler | Allison Bratzel71% | $65 → $62 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | — | Wells Fargo | Yanan Zhu43% | $82 → $77 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay55% | $70 → $65 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | — | RBC Capital | Luca Issi45% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 08/26/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $50 → $55 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay55% | $64 → $70 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Goldman Sachs | Salveen Richter51% | $33 → $37 | Maintains | Sell | Get Alert |
| 08/02/2024 | Buy Now | — | Barclays | Gena Wang51% | $45 → $51 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | — | BMO Capital | Kostas Biliouris34% | $67 → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/24/2024 | Buy Now | — | Leerink Partners | Mani Foroohar50% | $53 → $62 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/23/2024 | Buy Now | — | TD Cowen | Yaron Werber37% | $54 → $59 | Maintains | Buy | Get Alert |
| 07/23/2024 | Buy Now | — | B of A Securities | Jason Gerberry62% | $67 → $68 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | — | B of A Securities | Jason Gerberry62% | $64 → $67 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | — | Jefferies | Akash Tewari43% | $29 → $75 | Upgrade | Underperform → Buy | Get Alert |
| 06/27/2024 | Buy Now | — | Stifel | Paul Matteis43% | $50 → $53 | Maintains | Hold | Get Alert |
| 06/14/2024 | Buy Now | — | Bernstein | William Pickering38% | — | Upgrade | Underperform → Market Perform | Get Alert |
| 06/03/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Wells Fargo | Yanan Zhu43% | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | — | Oppenheimer | Jay Olson62% | $72 → $75 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | — | Oppenheimer | Jay Olson62% | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | Buy Now | — | Oppenheimer | Jay Olson62% | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | — | Piper Sandler | Do Kim54% | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | — | RBC Capital | Luca Issi45% | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | — | Piper Sandler | Do Kim54% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | — | B of A Securities | Jason Gerberry62% | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | Buy Now | — | Needham | Joseph Stringer64% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | — | Stifel | Paul Matteis43% | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | — | Goldman Sachs | Salveen Richter51% | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | Buy Now | — | Morgan Stanley | Michael Ulz66% | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | — | B of A Securities | Jason Gerberry62% | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | Buy Now | — | RBC Capital | Luca Issi45% | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | — | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
| 09/27/2023 | Buy Now | — | Morgan Stanley | Michael Ulz66% | $42 → $45 | Maintains | Equal-Weight | Get Alert |
| 09/27/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | — | Citigroup | David Lebowitz56% | $36 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | Buy Now | — | Piper Sandler | Do Kim54% | → $58 | Assumes | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | — | RBC Capital | Luca Issi45% | → $65 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | — | Citigroup | David Lebowitz56% | $30 → $36 | Upgrade | Sell → Neutral | Get Alert |
| 05/04/2023 | Buy Now | — | Wells Fargo | Vanck Zhu75% | $92 → $88 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | — | Barclays | Gena Wang51% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | — | Morgan Stanley | Michael Ulz66% | $40 → $42 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | — | Bernstein | William Pickering38% | → $31 | Initiates | → Underperform | Get Alert |
| 02/23/2023 | Buy Now | — | SVB Leerink | Mani Foroohar50% | $34 → $27 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | Buy Now | — | RBC Capital | Luca Issi45% | → $65 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | — | BMO Capital | Gary Nachman59% | $70 → $67 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | — | Barclays | Gena Wang51% | $44 → $40 | Maintains | Equal-Weight | Get Alert |
| 02/23/2023 | Buy Now | — | Needham | Joseph Stringer64% | → $60 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | — | SVB Leerink | Joseph Schwartz64% | $33 → $34 | Maintains | Market Perform | Get Alert |
| 01/23/2023 | Buy Now | — | SVB Leerink | Mani Foroohar50% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 01/19/2023 | Buy Now | — | Piper Sandler | Do Kim54% | $60 → $62 | Maintains | Overweight | Get Alert |
| 12/21/2022 | Buy Now | — | Morgan Stanley | Michael Ulz66% | $56 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/10/2022 | Buy Now | — | Morgan Stanley | Andrew Galler34% | $57 → $56 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | — | Citigroup | David Lebowitz56% | $28 → $31 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | — | SVB Leerink | Mani Foroohar50% | $30 → $26 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | — | Morgan Stanley | Andrew Galler34% | $30 → $57 | Upgrade | Underweight → Overweight | Get Alert |
| 08/10/2022 | Buy Now | — | Citigroup | David Lebowitz56% | $26 → $28 | Maintains | Sell | Get Alert |
| 08/10/2022 | Buy Now | — | RBC Capital | Luca Issi45% | $67 → $64 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | — | Piper Sandler | Do Kim54% | $55 → $58 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | — | Oppenheimer | Justin Kim37% | → $59 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS) stock?
The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by HC Wainwright & Co. on June 26, 2025. The analyst firm set a price target for $50.00 expecting IONS to rise to within 12 months (a possible 25.62% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by HC Wainwright & Co., and Ionis Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on July 24, 2024 when Leerink Partners raised their price target to $62. Leerink Partners previously had a market perform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on August 2, 2024 when BMO Capital changed their price target from $67 to $60 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on June 26, 2025 so you should expect the next rating to be made available sometime around June 26, 2026.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a reiterated with a price target of $50.00 to $50.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $39.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
